Department of Chemistry and Biochemistry, University of Oregon, Eugene, OR 97403.
Institute of Molecular Biology, University of Oregon, Eugene, OR 97403.
Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2208029119. doi: 10.1073/pnas.2208029119. Epub 2022 Oct 4.
Stability constrains evolution. While much is known about constraints on destabilizing mutations, less is known about the constraints on stabilizing mutations. We recently identified a mutation in the innate immune protein S100A9 that provides insight into such constraints. When introduced into human S100A9, M63F simultaneously increases the stability of the protein and disrupts its natural ability to activate Toll-like receptor 4. Using chemical denaturation, we found that M63F stabilizes a calcium-bound conformation of hS100A9. We then used NMR to solve the structure of the mutant protein, revealing that the mutation distorts the hydrophobic binding surface of hS100A9, explaining its deleterious effect on function. Hydrogen-deuterium exchange (HDX) experiments revealed stabilization of the region around M63F in the structure, notably Phe37. In the structure of the M63F mutant, the Phe37 and Phe63 sidechains are in contact, plausibly forming an edge-face π-stack. Mutating Phe37 to Leu abolished the stabilizing effect of M63F as probed by both chemical denaturation and HDX. It also restored the biological activity of S100A9 disrupted by M63F. These findings reveal that Phe63 creates a molecular staple with Phe37 that stabilizes a nonfunctional conformation of the protein, thus disrupting function. Using a bioinformatic analysis, we found that S100A9 proteins from different organisms rarely have Phe at both positions 37 and 63, suggesting that avoiding a pathological stabilizing interaction indeed constrains S100A9 evolution. This work highlights an important evolutionary constraint on stabilizing mutations, namely, that they must avoid inappropriately stabilizing nonfunctional protein conformations.
稳定性限制了进化。虽然人们对破坏稳定性的突变的限制有了很多了解,但对稳定突变的限制却知之甚少。我们最近在先天免疫蛋白 S100A9 中发现了一个突变,该突变为了解这种限制提供了线索。当引入到人类 S100A9 中时,M63F 同时增加了蛋白质的稳定性,并破坏了其激活 Toll 样受体 4 的天然能力。使用化学变性,我们发现 M63F 稳定了 hS100A9 的钙结合构象。然后我们使用 NMR 解决了突变蛋白的结构,揭示了该突变扭曲了 hS100A9 的疏水性结合表面,解释了其对功能的有害影响。氢氘交换 (HDX) 实验表明,在结构中 M63F 周围区域的稳定性增加,特别是 Phe37。在 M63F 突变体的结构中,Phe37 和 Phe63 侧链相互接触,可能形成边缘-面 π 堆积。将 Phe37 突变为亮氨酸,如化学变性和 HDX 所探测到的,消除了 M63F 的稳定作用。它还恢复了 M63F 破坏的 S100A9 的生物学活性。这些发现表明,Phe63 与 Phe37 形成了一个分子固定器,稳定了蛋白质的无功能构象,从而破坏了功能。通过生物信息学分析,我们发现来自不同生物体的 S100A9 蛋白很少在位置 37 和 63 处都有苯丙氨酸,这表明避免病理性稳定相互作用确实限制了 S100A9 的进化。这项工作强调了对稳定突变的一个重要进化限制,即它们必须避免不恰当地稳定无功能的蛋白质构象。